notificationsアラート設定
~
検索条件をクリア

アブストラクト

Title LEPの効果・副効用
Subtitle 特集 女性のQOL向上のためのホルモン治療
Authors 樋口毅*
Authors (kana)
Organization *弘前大学大学院保健学研究科看護学領域
Journal 医学と薬学
Volume 77
Number 10
Page 1357-1365
Year/Month 2020 / 10
Article 報告
Publisher 自然科学社
Abstract 「はじめに」 低用量エストロゲン・プロゲスチン配合薬(low dose estrogen progestin : LEP)とは, 一錠あたりに50μg未満のエチニルエストラジオール(ethinyl estradiol : EE)とプロゲスチンを含有する低用量経口避妊薬(oral contraceptive : OC)と同じ分類の薬剤群である. 避妊目的でのOC使用者の長期かつ詳細な観察から, OCには月経関連トラブルの改善効果に代表される副効用が報告され, 米国の診療ガイドラインでも認められてきた. 本邦ではOCの副効用の一つである月経困難症の治療を保険診療で行う目的で2008年LEPが登場した. OC・LEPには月経関連トラブルへの効果の他にも, にきび, 多毛症の改善, さらに卵巣癌, 子宮体癌, 大腸癌の発症リスク低下などの副効用も報告されており, 服薬に際してはこれらの多様な効果についての説明も必要となる. 本項ではこれらの効果・副効用について述べる.
Practice 医学総合
Keywords 月経関連トラブル, 子宮内膜症, にきび, 悪性腫瘍
  • 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
download全文ダウンロード(1.03MB)

参考文献

  • 1) 日本産科婦人科学会 編:低用量経口避妊薬,低用量エストロゲン・プロゲスチン配合薬(OC・LEPガイドライン)2015年度版, p10, 日本産科婦人科学会事務局, 東京,2015.
  • 2) Committee on practice bulletins-gynecology:Noncontraceptive uses of hormonal contraceptives. Practice Bulletin 110:1-13,2010.
  • 3) 日本産科婦人科学会 編:産科婦人科用語集・用語解説集 改訂第4版, p60, 日本産科婦人科学会事務局, 東京,2018.
  • 4) 日本産科婦人科学会 編:子宮内膜症取扱規約 第2部 治療編・診療編, pp.15-32, 金原出版, 東京,2010.
  • 5) Harada T, Momoeda M, Terakawa N, et al:Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea:a placebo-controlled, double-blind, randomized trial. Fertil Steril 95:1928-1931,2011.
    pubmed
残りの33件を表示する
  • 6) Harada T, Momoeda M, Taketani Y, et al:Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis:a placebo-controlled, double-blind, randomized trial. Fertil Steril 90:1583-1588,2008.
    pubmed
  • 7) Momoeda M, Hayakawa M, Shimazaki Y, et al:Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. Int J Womens Health 6:989-998,2014.
    pubmed
  • 8) 日本産科婦人科学会 編:産科婦人科用語集・用語解説集 改訂第4版, p34, 日本産科婦人科学会事務局, 東京,2018.
  • 9) Munro MG, Critchley HO, Broder MS, et al:FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynecol Obstet 113:3-13,2010.
  • 10) Fraser I, McCarron G:Randomized trial of 2 hormonal and 2 prostaglandin inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 31:66-70,1991.
    pubmed
  • 11) Lethaby A, Wise MR, Weterings MA, et al:Combined hormonal contraceptives for heavy menstrual bleeding:Cochrane Database Syst Rev 2:CD000154,2019.
    pubmed
  • 12) National Institute for Health and Clinical Excellence. Heavy Menstrual Bleeding (NICE Clinical Guideline 44),2018.
  • 13) Vercellini P, Frontino G, De Giorgi O, et al:Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 80:560-563,2003.
  • 14) Guzick DS, Huang LS, Broadman BA, et al:Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril 95:1568-1573,2011.
    pubmed
  • 15) Harada T, Kosaka S, Elliesen J, et al:Ethinylestradiol 20μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain:a randomized controlled trial. Fertil Steril 108:798-805,2017.
  • 16) Taniguchi F, Enatsu A, Ota I, et al:Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma. Euro J Obstet Gynecol Reprod Biol 191:116-120,2015.
  • 17) Harada T, Kosaka S, Elliesen J, et al:Ethinylestradiol 20μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain:a randomized controlled trial. Fertil Steril 108:798-805,2017.
  • 18) Ferrero S, Venturini PL, Remorgida V:Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies. Arch Gynecol Obstet 287:447-453,2013.
    pubmed
  • 19) Ferrari S, Persico P, DI Puppo F, et al:Continuous low dose oral contraceptive in the treatment of colorectal endometriosis evaluated by rectal endoscopic ultrasonography. Acta Obstet et Gynecol Scand 91:699-703,2012.
    pubmed
  • 20) Fedele L, Bianchi S, Montefusco S, et al:A gonadotropin-releasing hormone agonist versus a continuous oral contraceptive pill in the treatment of bladder endometriosis. Fertil Steril 90:183-184,2008.
    pubmed
  • 21) Vercellini P, DE Matteis S, Somigliana E, et al:Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence:a systematic review and meta-analysis. Acta Obstet Gynecol Scand 92:8-16,2013.
    pubmed
  • 22) Seracchioli R, Mabrouk M, Frasca C, et al:Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence:a randomized controlled trial. Fertil Steril 93:52-56,2010.
    pubmed
  • 23) 田坂慶一:13. 月経前症候群と黄体ホルモン. 特集黄体ホルモンの基礎から臨床まで, 産科と婦人科 82:797-802,2015.
  • 24) Lopez LM, Kaptein AA, Helmerhorst FM:Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2:CD006586,2012.
    pubmed
  • 25) Takeda T, Kondo A, Koga S, et al:Effectiveness of ethinylestradiol/drospirenone for premenstrual symptoms in Japanese patients with dysmenorrhea:Open-label pilot study. J Obstet Gynaecol Res 41:1584-1590,2015.
    pubmed
  • 26) Coffee AL, Kuehl TJ, Willis S, et al:Oral contra-ceptives and premenstrual symptoms:comparison of a 21/7 and extended regimen. American journal of obstetrics and gynecology 195:1311-1319,2006.
  • 27) O' Connell K, Westhoff C:Pharmacology of hormonal contraceptives and acne. Cutis 81:8-12,2008.
    pubmed
  • 28) Zaenglein AL, Pathy AL, Schlosser BJ, et al:Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 74:945-973,2016.
    pubmed
  • 29) Marson JW, Baldwin HE:An Overview of Acne Therapy, Part 2:Hormonal Therapy and Isotretinoin. Dermatol Clin 37:195-203,2019.
    pubmed
  • 30) Hannaford PC, Selvaraj S, Elliott AM, et al:Cancer risk among users of oral contraceptives:cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 335:651,2007.
    pubmed
  • 31) 高松 潔,杉山重里,小川真理子,他:9. 悪性腫瘍のリスク. 特集 OC・LEP ガイドライン ポイントの解説, 産科と婦人科 83:171-181,2016.
  • 32) Havrilesky LJ, Gierisch JM, Coeytaux RR, et al:Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess(FullRep) 212:1-514,2013.
    pubmed
  • 33) Havrilesky LJ, Moorman PG, Lowery WJ, et al:Oral contraceptive pills as primary prevention for ovarian cancer:a systematic review and meta analysys. Obstet Gynecol 133:139-147,2013.
  • 34) Gierisch JM, Coeytaux RR, Urrutia RP, et al:Oral contraceptive use and risk of breast, cervical, colorectal, and endometorial cancers:a systematic review. Cancer Epidemiol Biomakers Prev 22:1931-1943,2013.
  • 35) International Collaboration of Epidemiological Studies of Cervical Cancer:Cervical cancer and hormonal contraceptives:collaborative reanalysis of individual data for 16573 women with cervical cancer and 35509 women without cervical cancer from 24 epidemiological studies. Lancet 370:1609-1621,2007.
  • 36) Iversen L, Fielding S, Lidegaard O, et al:Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark:prospective, nation-wide cohort study. BMJ 362:k3609,2018.
  • 37) Schlesselman JJ:Risk of endometrial cancer in relation to use of combined oral contraceptives. A practioner's guide to meta-analysis. Hum Reprod 12:1851-1863,1997.
  • 38) Vessey M, Painter R:Oral contraceptive use and cancer. Findings in a large cohort study,1968-2004. Br J Cancer 95:385-389,2006.
はじめての方へ
個人／法人会員登録のご案内